GLP-1 and GLP-1/GIP Agonists, Adverse Liver Outcomes and Type 2 DM

GLP-1 receptor agonists (such as semaglutide and liraglutide) and the dual GLP-1/GIP receptor agonist tirzepatide have been studied for their impact on major adverse liver outcomes (MALO) in patients with type 2 diabetes (T2D). These outcomes include severe liver conditions like cirrhosis, liver failure, hepatocellular carcinoma (HCC), and liver transplant, which are often linked to metabolic dysfunction-associated steatotic liver disease (MASLD).

MASLD is a growing concern globally, as its progression to cirrhosis and severe liver complications is closely tied to the severity of liver fibrosis. GLP-1 receptor agonists and dual GLP-1/GIP agonists have shown promise in improving metabolic health and reducing liver inflammation and fibrosis in previous studies.

In a large-scale real-world study using data from over 150 million patients, researchers compared tirzepatide, semaglutide, and liraglutide with DPP-4 inhibitors over a two-year follow-up period. Tirzepatide demonstrated the strongest protective effect, with a 47% lower risk of MALO compared to DPP-4 inhibitors, primarily by reducing cirrhosis and decompensated cirrhosis cases. Semaglutide also significantly reduced MALO risk, particularly for decompensated cirrhosis and hepatic encephalopathy. Liraglutide, however, did not show significant overall benefits, except for a slight reduction in ascites incidence.

The dual mechanism of tirzepatide (GLP-1 + GIP agonism) likely provides synergistic benefits by improving lipid metabolism, insulin sensitivity, and reducing hepatic inflammation and fibrosis. Both tirzepatide and semaglutide also improve glycemic control, body weight, and lipid profiles, further contributing to liver protection.

These findings suggest prioritizing tirzepatide or semaglutide for managing MASLD in T2D patients, with tirzepatide showing the most promise in reducing adverse liver outcomes.